SCHEMBL3033994

SCHEMBL3033994

COc1cnccc1OBOc1ccncc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
CYP1A2 P05177 3/20 0.41
CYP2E1 P05181 3/20 0.41
CYP2A6 P11509 3/20 0.41
CYP2B6 P20813 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 1/20 0.41
MAOA P21397 2/20 0.41
CHRNB4 P30926 2/20 0.39
CHRNA3 P32297 2/20 0.39
CYP2D6 P10635 2/20 0.37
CYP2C8 P10632 1/20 0.37
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CCNA1 P78396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765644 0.92 CA12 (0.46) CA12CA1CA2CA9CYP1A2
SCHEMBL2538708 0.84 CA12 (0.53) CA12CA1CA2CA9CYP1A2
Hydrochloric Acid SCHEMBL27935953 0.82 CA12 (0.52) CA12CA1CA2CA9CYP1A2
Formaldehyde SCHEMBL28867396 0.78 CA12 (0.53) CA12CA1CA2CA9CYP1A2
SCHEMBL16861325 0.77 CA12 (0.35) CA12CA1CA2CA9CYP1A2
Water SCHEMBL29088290 0.75 CHRNB4 (0.42) CA12CA1CA2CA9CYP1A2
Formic Acid SCHEMBL28858365 0.73 CA12 (0.49) CA12CA1CA2CA9CYP1A2
SCHEMBL12934590 0.73 CYP1A2 (0.49) CA12CA1CA2CA9CYP1A2
SCHEMBL1643772 0.72 LOXL2 (0.41) CA12CA1CA2CA9
SCHEMBL3026363 0.72 GAA (0.45) CA12CA1CA2CA9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367662-B2 Organic compounds NOVARTIS AG (CH) 2013-02-05 US disclosed
EP-2212323-B1 IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS NOVARTIS AG (CH) 2012-08-15 EP disclosed
US-20100210641-A1 Organic Compounds NOVARTIS AG (CH) 2010-08-19 US disclosed
EP-2212323-A2 IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050183-A2 IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS NOVARTIS AG (CH) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210641-A1 Organic Compounds ALK, ACVR1, ACVRL1 CA12 3392/4885CA1 4187/4885CA2 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.